A citation-based method for searching scientific literature

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters, Sangeeta Sawhney, Paul Strumph. Diabetes Care 2018
Times Cited: 52



Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell, William T Cefalu, Paul Strumph. Diabetes Care 2015
Times Cited: 99




List of shared articles



Times cited

Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2.
Helena W Rodbard, Andrea Giaccari, Rosemarie Lajara, John Stewart, Paul S Strumph, Juliana Oliveira, Pablo Lapuerta, Rita Castro. Diabetes Obes Metab 2020
0

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. BMJ 2019
23

Sotagliflozin: First Global Approval.
Anthony Markham, Susan J Keam. Drugs 2019
8

Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Kexin Li, Gaosi Xu. J Diabetes 2019
3

Evaluation of the safety of sodium-glucose co-transporter-2 inhibitors for treating patients with type 1 diabetes.
Weihao Wang, Lina Zhang, Xiaobei Pei, Qi Pan, Lixin Guo. Diabetes Obes Metab 2020
0

Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
Bryony E Langford, Marc Evans, Tao Haskins-Coulter, Molly O'Connor, Harriet E O Cant, Lucy A Eddowes, Christopher Edmonds, Amarjeet Tank. Diabetes Obes Metab 2020
1

A review of sotagliflozin for use in type 1 diabetes.
Wesley Nuffer, Briana Williams, Jennifer M Trujillo.  2019
1

Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Kajal Patel, Antonia Carbone. Ann Pharmacother 2019
6

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
64

Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
5

Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes.
Marc S Rendell. Expert Rev Endocrinol Metab 2018
2

What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
5

Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes.
Diana Isaacs, Stephanie Yager, Marcie Parker, Lauren Wolfe, Jennifer Luxenburg, Sanela Lekic. Ann Pharmacother 2019
0

Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Jingli Lu, Lijuan Tang, Haiyang Meng, Junjie Zhao, Yan Liang. Diabetes Metab. Res. Rev. 2019
6

Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis.
Mao-Bing Chen, Rui-Jun Xu, Qi-Han Zheng, Xu-Wen Zheng, Hua Wang. Medicine (Baltimore) 2020
0

SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Simeon I Taylor, Jenny E Blau, Kristina I Rother, Amber L Beitelshees. Lancet Diabetes Endocrinol 2019
8

Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice.
Ane Bayona Cebada, Lía Nattero-Chávez, Sara Alonso Díaz, Héctor F Escobar-Morreale, Manuel Luque-Ramírez. Diabetes Technol. Ther. 2020
1

Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
Yoon Ji Kim, Seun Deuk Hwang, Soo Lim. Front Endocrinol (Lausanne) 2020
0

Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
Chantal Mathieu, Paresh Dandona, Moshe Phillip, Tal Oron, Marcus Lind, Lars Hansen, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2019
16

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J. Clin. Endocrinol. Metab. 2020
0


Longstocking, LLC. © 2020
Home | About Us | FAQs | Terms & Privacy